Komori
Semi-Annual Report219AHeartseed Inc.Pharmaceuticals

Semi-Annual Report — FY2026 H1

What Heartseed Inc. reported for the period from 2026-01-01 to 2026-12-31.

How much it says
38Thin
What moved here
9named for the first time
Its own wording
13terms
Which filing this is
4/ 4newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the interim accounting period, the company completed analysis of all 10 cases in the HS-001 LAPiS trial and reported, among other matters, that no safety concerns affecting the primary endpoints had been identified. The filing also states that the first patient with dilated cardiomyopathy was treated in the HS-005 EMERALD trial and that the independent safety evaluation committee approved continuation of the trial. Revenue was ¥467,370 thousand and interim net loss was ¥554,307 thousand.

Komori's summary of this document, not the document's own words.
38Thin
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
Magnitude of Change
7
Almost nothing
Strategic Shift
46
Typical
Capital Movements
50
Typical
Disclosure Gaps
15
Almost nothing
Future Commitments
53
Typical
Change in Risk
55
Typical
Financial and Capital Policy
7
Almost nothing
Product portfolio
55
Typical
Technology Position
19
Almost nothing
Confidence in Strategic Bets
R&D spend8億円Money spent making new things.
Cash left over-5億円Cash from the business, less what went into equipment.
Spent on equipment1百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
Heartseed Inc. — FY2026 H1 | Komori